vs

Side-by-side financial comparison of Alkermes plc. (ALKS) and PicoCELA Inc. (PCLA). Click either name above to swap in a different company.

Alkermes plc. is the larger business by last-quarter revenue ($384.5M vs $252.6M, roughly 1.5× PicoCELA Inc.). Alkermes plc. runs the higher net margin — 12.8% vs -125.2%, a 138.0% gap on every dollar of revenue. Alkermes plc. produced more free cash flow last quarter ($170.0M vs $-256.6M).

Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio.

PicoCELA Inc. is a global technology company specializing in low-power, high-reliability wireless connectivity solutions, including Wi-Fi HaLow modules and edge network infrastructure. It caters to industrial IoT, smart city, retail, and smart home segments, with a primary operational footprint across Asia, North America, and European markets.

ALKS vs PCLA — Head-to-Head

Bigger by revenue
ALKS
ALKS
1.5× larger
ALKS
$384.5M
$252.6M
PCLA
Higher net margin
ALKS
ALKS
138.0% more per $
ALKS
12.8%
-125.2%
PCLA
More free cash flow
ALKS
ALKS
$426.6M more FCF
ALKS
$170.0M
$-256.6M
PCLA

Income Statement — Q4 FY2025 vs Q2 FY2025

Metric
ALKS
ALKS
PCLA
PCLA
Revenue
$384.5M
$252.6M
Net Profit
$49.3M
$-316.2M
Gross Margin
88.0%
Operating Margin
15.1%
-114.8%
Net Margin
12.8%
-125.2%
Revenue YoY
-10.6%
Net Profit YoY
-66.3%
EPS (diluted)
$0.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALKS
ALKS
PCLA
PCLA
Q4 25
$384.5M
Q3 25
$394.2M
Q2 25
$390.7M
Q1 25
$306.5M
$252.6M
Q4 24
$430.0M
Q3 24
$378.1M
Q2 24
$399.1M
Q1 24
$350.4M
Net Profit
ALKS
ALKS
PCLA
PCLA
Q4 25
$49.3M
Q3 25
$82.8M
Q2 25
$87.1M
Q1 25
$22.5M
$-316.2M
Q4 24
$146.5M
Q3 24
$92.4M
Q2 24
$91.4M
Q1 24
$36.8M
Gross Margin
ALKS
ALKS
PCLA
PCLA
Q4 25
88.0%
Q3 25
86.9%
Q2 25
87.3%
Q1 25
83.9%
Q4 24
85.6%
Q3 24
83.3%
Q2 24
84.6%
Q1 24
83.3%
Operating Margin
ALKS
ALKS
PCLA
PCLA
Q4 25
15.1%
Q3 25
22.6%
Q2 25
23.8%
Q1 25
4.5%
-114.8%
Q4 24
37.8%
Q3 24
27.7%
Q2 24
27.5%
Q1 24
12.4%
Net Margin
ALKS
ALKS
PCLA
PCLA
Q4 25
12.8%
Q3 25
21.0%
Q2 25
22.3%
Q1 25
7.3%
-125.2%
Q4 24
34.1%
Q3 24
24.4%
Q2 24
22.9%
Q1 24
10.5%
EPS (diluted)
ALKS
ALKS
PCLA
PCLA
Q4 25
$0.29
Q3 25
$0.49
Q2 25
$0.52
Q1 25
$0.13
Q4 24
$0.88
Q3 24
$0.55
Q2 24
$0.53
Q1 24
$0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALKS
ALKS
PCLA
PCLA
Cash + ST InvestmentsLiquidity on hand
$388.6M
$456.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.8B
$354.8M
Total Assets
$2.5B
$1.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALKS
ALKS
PCLA
PCLA
Q4 25
$388.6M
Q3 25
$616.4M
Q2 25
$521.2M
Q1 25
$399.8M
$456.8M
Q4 24
$291.1M
Q3 24
$396.3M
Q2 24
$535.1M
Q1 24
$420.8M
Stockholders' Equity
ALKS
ALKS
PCLA
PCLA
Q4 25
$1.8B
Q3 25
$1.7B
Q2 25
$1.6B
Q1 25
$1.5B
$354.8M
Q4 24
$1.5B
Q3 24
$1.3B
Q2 24
$1.3B
Q1 24
$1.3B
Total Assets
ALKS
ALKS
PCLA
PCLA
Q4 25
$2.5B
Q3 25
$2.3B
Q2 25
$2.3B
Q1 25
$2.1B
$1.2B
Q4 24
$2.1B
Q3 24
$2.2B
Q2 24
$2.2B
Q1 24
$2.1B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALKS
ALKS
PCLA
PCLA
Operating Cash FlowLast quarter
$170.1M
$-245.6M
Free Cash FlowOCF − Capex
$170.0M
$-256.6M
FCF MarginFCF / Revenue
44.2%
-101.6%
Capex IntensityCapex / Revenue
0.0%
4.3%
Cash ConversionOCF / Net Profit
3.45×
TTM Free Cash FlowTrailing 4 quarters
$480.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALKS
ALKS
PCLA
PCLA
Q4 25
$170.1M
Q3 25
$101.7M
Q2 25
$150.2M
Q1 25
$98.8M
$-245.6M
Q4 24
$190.4M
Q3 24
$81.6M
Q2 24
$146.0M
Q1 24
$21.1M
Free Cash Flow
ALKS
ALKS
PCLA
PCLA
Q4 25
$170.0M
Q3 25
$84.4M
Q2 25
$137.2M
Q1 25
$88.7M
$-256.6M
Q4 24
$180.6M
Q3 24
$73.3M
Q2 24
$138.9M
Q1 24
$12.8M
FCF Margin
ALKS
ALKS
PCLA
PCLA
Q4 25
44.2%
Q3 25
21.4%
Q2 25
35.1%
Q1 25
28.9%
-101.6%
Q4 24
42.0%
Q3 24
19.4%
Q2 24
34.8%
Q1 24
3.6%
Capex Intensity
ALKS
ALKS
PCLA
PCLA
Q4 25
0.0%
Q3 25
4.4%
Q2 25
3.3%
Q1 25
3.3%
4.3%
Q4 24
2.3%
Q3 24
2.2%
Q2 24
1.8%
Q1 24
2.4%
Cash Conversion
ALKS
ALKS
PCLA
PCLA
Q4 25
3.45×
Q3 25
1.23×
Q2 25
1.72×
Q1 25
4.40×
Q4 24
1.30×
Q3 24
0.88×
Q2 24
1.60×
Q1 24
0.57×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ALKS
ALKS

Vivitrol$124.1M32%
Aristada And Aristada Initio$97.2M25%
LYBALVI$94.1M24%
Royalty$65.7M17%
Manufacturing Revenue$3.3M1%

PCLA
PCLA

Revenue from product$179.1M71%
Revenue from SaaS, Maintenance and others$42.4M17%
Revenue from product – related party$31.0M12%

Related Comparisons